Is BTKi or BCL2i preferable as first novel therapy in patients with CLL? The case for BCL2i
- Author(s)
- Seymour, JF;
- Details
- Publication Year 2022-02-22,Volume 6,Issue #4,Page 1365-1370
- Journal Title
- Blood Advances
- Publication Type
- Commentary
- Keywords
- Agammaglobulinaemia Tyrosine Kinase; Humans; *Leukemia, Lymphocytic, Chronic, B-Cell/drug therapy; Protein Kinase Inhibitors
- Department(s)
- Haematology
- PubMed ID
- 34965297
- Publisher's Version
- https://doi.org/10.1182/bloodadvances.2019001205
- Open Access at Publisher's Site
https://doi.org/10.1182/bloodadvances.2019001205- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2025-04-04 12:33:46
Last Modified: 2025-04-04 12:35:17